ABUS Earnings Date: Nov 16, 2026 (Estimated) — Arbutus Biopharma Corp
NASDAQ · Healthcare · Biotechnology
Updated
When is ABUS's next earnings date?
Arbutus Biopharma Corp (ABUS) is expected to report Q3 2026 earnings on Monday, November 16, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.02 on revenue of $1.0M.
How did ABUS do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Arbutus Biopharma Corp posted EPS of -$0.03 versus the -$0.02 estimate, a miss of 0.0%. Revenue was $1.0M against a $700,000 estimate. The stock's 1-day post-earnings move was -1.7%.
How much does ABUS stock move after earnings?
ABUS beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.2% (up or down) in the day after earnings.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.02 | -0.03 | +0.00% | $1.0M | ❌ Miss | -1.71% | +3.64% | +9.64% |
| 2026-05-13 | Q1 2026 | -0.06 | 0.87 | +1550.00% | $179.1M | ✅ Beat | +0.00% | -2.55% | -0.46% |
| 2026-03-23 | Q4 2025 | -0.04 | -0.01 | +75.00% | $1.1M | ✅ Beat | +4.25% | +1.18% | +4.48% |
| 2025-11-13 | Q3 2025 | -0.04 | -0.04 | +0.00% | $529,000 | ➖ Inline | -5.79% | -11.78% | -2.69% |
| 2025-08-06 | Q2 2025 | -0.06 | 0.01 | +116.67% | $10.7M | ✅ Beat | +1.76% | -0.29% | +17.60% |
| 2025-03-27 | Q4 2024 | -0.12 | -0.07 | +41.67% | $1.6M | ✅ Beat | -2.39% | +4.78% | -1.79% |
| 2024-11-06 | Q3 2024 | -0.09 | -0.10 | -11.11% | $1.3M | ❌ Miss | -1.01% | -8.08% | -8.33% |
| 2024-08-01 | Q2 2024 | -0.10 | -0.11 | -10.00% | $1.7M | ❌ Miss | +1.06% | -6.90% | +1.59% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $10.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License | 93.4% | $9.6M | 0.0% | $1.2M | $800K | $9.6M | $9.6M |
| Service, Other | 4.9% | $500K | 0.0% | — | — | $500K | $500K |
| Non-Cash Royalty | 1.8% | $180K | -65.8% | $1.1M | $448K | $526K | $249K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.